Background: HIV-1 invades the central nervous system early after infection when macrophage infiltration of the brain is low but myelin pallor is suggestive of bloodbrain-barrier damage. High-level plasma viremia is a likely source of brain infection. To understand the invasion route, we investigated virus penetration across in vitro models with contrasting paracellular permeability subjected to TNF-a. Materials and Methods: Blood-brain-barrier models constructed with human brain microvascular endothelial cells, fetal astrocytes, and collagen I or fibronectin matrix responded in a dose-related fashion to cytokines
INTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) is found in the cerebrospinal fluid (CSF) of 554 Molecular Medicine, Volume 3, Number 8, August 1997 pseudorabies virus (4) and with HIV-1 (across epithelial monolayers) (5); a paracellular route between endothelial cells (shown here); endothelial cell infection as suggested with simian immunodeficiency virus (SIV) (6) and lymphotropic HIV-1 (7, 8) ; disruption of the blood-brain barrier by perivascular "activated" macrophages (9) ; and the "Trojan horse" mechanism, postulated a decade ago (10) and recently shown mechanistically by transmigration of LPS-activated monocytes carrying HIV-1 across a BBB model (1 1) . At an early stage of AIDS, however, infectious virus is generally not found in circulating blood monocytes (12) , and in the brain, macrophages, multinucleated giant cells, and viral proteins are low or absent, whereas vasculitis and myelin pallor, reflecting BBB damage, are common (13) . Tumor necrosis factor a (TNF-a) is a potential cause of this damage because of its ability to increase the permeability of brain endothelial cells (14) . Furthermore, early after the infection plasma viremia titers may be extremely high-up to 107 viral RNA copies per ml of blood (1 5,16) . BBB integrity is therefore of key importance in protection against infection of the brain by HIV-1 viremia.
To investigate the role of BBB in HIV-1 infection of the brain, we developed an in vitro model of the BBB (17) which includes the components of the human BBB: brain endothelial cells, astrocytes, and the basement membrane matrix. The results of this study show that endothelial cells play a key role as a barrier to HIV-1, which can, however, penetrate between endothelial cells by a paracellular route opened by TNF-a. These observations suggest that in vivo the intact BBB may initially provide protection against blood-borne HIV-1; however, the BBB becomes compromised by HIV-1 -induced inflammatory cytokines, chemokines, and leukotrienes acting in a paracrine and autocrine manner on brain endothelial cells.
MATERIALS AND METHODS Cell Culture and Virus
Adult brain microvascular endothelial cells were derived from nonepileptogenic lateral temporal cortex tissues obtained during surgical removal of epileptogenic foci in the medial temporal lobe (18, 19) . Pediatric brain endothelial cells were prepared from surgical specimens of the cerebral cortex from children with seizure disorders (20) . The brain tissue was dissociated and cultured by the techniques described previously (19, 20) , and the outgrowing cells were cultured in DME/F- 12 (Sigma, St. Louis, MO) with 10% fetal bovine serum, 25 mM HEPES (pH 7.2-7.4), bicarbonate (0.14%), endothelial cell growth supplement (50 ,g/ml) (H-Neurext, Upstate Biotechnology, Lake Placid, NY), penicillin (100 u/ml), streptomycin (100 ,ug/ml), and fungizone (0.25 ,ug/ml) (referred to as DME-S) to which heparin was initially added (100 jig/ml). Each cell line had cobblestone morphology, and each was positive for endothelial cell markers, factor VIII-related antigen, and Ulex europaeus agglutinin, as determined by flow cytometric analysis and immunocytochemistry with rabbit antibody to von Willebrand factor and Ulex europeus agglutinin (DAKO, Carpinteria, CA) (11) . The cells were negative by staining with mouse antihuman glial fibrillary acidic protein and mouse anti-CD56 and anti-CD68 antibodies. Glucose transporter isoform type 1 (GLUT-1) and occludin antigens were demonstrated at an early passage by immunocytochemical staining utilizing rabbit antibody to GLUT-1 (21) or occludin (Zymed Labs., South San Francisco, CA), respectively. Light microscopy and transmission electron microscopy revealed uniformly flat and tightly adjoining endothelial cells covering the porous membrane completely and displaying areas of cell membrane fusion between adjoining cells resembling zonula adhaerens (desmosome) junctions (22) . Human fetal astrocytes (HFA) were prepared as described by Tornatore et al. (23) and were 100% positive by immunocytochemistry with rabbit antibody to glial fibrillary acidic protein (DAKO). The A3.01 cell line, a human T cell line derived from the buffy coat of a patient with lymphoblastic leukemia and susceptible to HIV-1, was obtained from the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH (24) and used for infectious virus assay.
HIV-lJR-FL (25) , an HIV-1 strain isolated from the frontal lobe tissue of a patient with AIDS encephalopathy, was grown in normal human umbilical cord mononuclear cells stimulated by interleukin-2 (IL-2; Amgen, Thousand Oaks, CA) (10 U/ml) and phytohemagglutinin-A (Sigma Chemical Co., St. Louis, MO) (0.5 ,ug/ml) for 10 days, after which the supernatant medium was separated by centrifugation and stored frozen in aliquots.
Blood-Brain-Barrier Model The model was constructed in tissue culture inserts with Cyclopore polyethylene terephthalate membranes (2 X 106 pores/cm2 [pore diameter of 3 ,um]) coated with collagen type I (rat tail) and human fibronectin (50 ,ug/ml) (all from Collaborative Biomedical Products, Bedford, MA) with brain endothelial cells on the top (bloodside) and human fetal astrocytes on the bottom (brain-side) according to previously published concepts (26, 27) . MATRIGEL basement membrane matrix (Becton Dickinson/Collaborative Biomedical Products, Bedford, MA) was tested but not used further. Adult endothelial cells in an in vitro passage 2-6 were used in most experiments. Pediatric endothelial cells were used in the experiment described in Fig. 4 . To coat the lower surface with astrocytes, a suspension of 3 x 104 astrocytes in 1 ml of DME-S was placed in a cut-off bulb-end of a sterile disposable pipette (Liquipette, Elkay Productis, Shrewsbury, MA) and the lower end of the insert was inserted aseptically into the bulb, which made a tight seal. The bulb with the insert was then inverted and incubated at 370C for 4 hr to allow the HFA to attach to the membrane. Following this incubation, the bulb was removed and the insert placed right side up in a 24-well tray. A suspension of 0.4 X 104 brain endothelial cells in 0.31 ml DME-S was placed in the upper chamber of the insert and 1 ml of DME-S was placed in the lower chamber.
IL-6 Assay IL-6 was assayed by ELISA as described previously (28) .
Electrical Resistance This was measured using the Millicell-ERS apparatus (Millipore, Bedford, Mass) by means of AC current after placing one Ag/AgCl electrode (World Precision Instruments, Sarasota, FL) in the upper chamber (0.1-0.2 ml media) and the other electrode in the lower chamber of the model (0.5 ml media). Electrodes were sterilized using 95% alcohol followed by rinsing in distilled water, and were maintained at a constant distance (0.6 cm) between electrodes. 
Transmigration of Monocytes
Human blood monocytes were obtained by a modification of the Recalde procedure (30) . For inhibition studies, the lower chamber was treated with IL-1p (2 ng/ml) and monocyte chemotactic protein 1 (MCP-1) (R&D Systems, Minneapolis, MN) (10 ng/ml), and the upper chamber was treated with each monoclonal antibody at a final concentration of 20 ,ug/ml for 1.5 hr. The following antibodies were used with specificity (identification): (a) f1 (15/7), /32(IB4), a4 (L25) integrins (Athena Neurosciences, South San Francisco, CA); (b) VCAM-1 (11/33 and 11/47) (Athena Neurosciences), VCAM-1 (4B9) (T. Carlos (31, 32) . Briefly, 50-,uL samples were diluted 1:4 with phosphate-buffered saline (PBS) and vortexed for 5 sec. Two hundred microliters of each sample was added to Sarstedt 2.0-ml tubes containing 600 ,uL lysis reagent together with the indicated volume of quality standard (QS) for the QS lot, tubes were incubated for 10 min at 20°C, and 800 ,uL isopropanol was added. After again vortexing for 5 sec, samples were centrifuged for 15 min at 16,000 g, the supernatants discarded, and the pellets washed twice with 70% ethanol and resuspended in 400 ,uL specimen diluent. Then 50-,uL samples were added to MicroAmp tubes containing 50 ,tL master PCR mix. Reverse transcription was performed for 2 min at 500C and 30 min at 600C. Polymerase chain reaction (PCR) amplification was performed using the following conditions: 950C for 10 sec, 55°C for 10 sec, 720C for 10 sec (4 cycles), nd then 90°C for 10 sec, 600C for 10 sec, and 720C for 10 sec (26 cycles). Terminal extension was performed for 15 min at 720C. Following amplification, products were denatured by adding 100 ,tL denaturing solution, 25 ,uL of each sample was added to 100 ,uL of hybridization solution in the assay microwell plate. Samples were then serially diluted (1:5, 25 ,tL) and plates incubated for 1 hr at 370C and washed five times. After addition of avidin-HRP conjugate (100 ,uL) to each well, the plates were incubated for 15 (26, 27) with endothelial cells and extracellular matrix on the upper side and astrocytes on the lower side of a porous membrane (Fig. 1) . The extracellular matrix communicates via integrins to endothelial cells providing the signals for the formation of tight intercellular junctions (34) . The models constructed on collagen I or IV had a relatively low permeability coefficient for the paracellular marker inulin (0.0009-0.001 cm/min) and a relatively high electrical resistance (76-98 f.cm2), whereas those on fibronectin matrix had a relatively high 3 . TNF-a enhancement of HIV-1 penetration is greater in models with high basal permeability compared with models with low basal permeability Models (4 days in culture) were were treated with DME-S (circles), DME-S with TNF-a (10 ng/ml) (triangles), or DME-S with TNF-a (100 ng/ml) (squares) for 2 hr prior to and during the whole experiment. HIV-1 was placed in the upper chamber (2.1 ng in A and B, and 50 pg in C). Samples (50 ,uL) for virus assay were removed from the lower chamber at indicated intervals and were measured by infectious virus assay (A and B), or antibodies to VCAM-1 were found to inhibit cell transmigration by up to 50% (data not shown). Monocyte transmigration was regulated by endothelial cells in synergy with the extracellular matrix but not by the endothelial monolayer alone (Table 1) .
TNF-a, a proinflammatory cytokine, increases the paracellular permeability of bovine brain endothelial cells (14, 37 (38) . In the BBB model, both TNF-a and RMP-7 increased inulin permeability within the first 4 hr similarly in a dose-responsive fashion by up to 200% (TNF-a 100 ng/ml) (0.05 < p < 0.10) and up to 225% (RMP-7 10 ng/ml) (0.05 < p < 0.10) (Fig. 2) . (Fig. 3A, B RT-PCR, to determine the numbers of viral RNA copies (Figs. 3C, 5 ), the barrier function was found to be close to 100% for the first hour postinfection. The efficiency of the barrier at 1 hr was evaluated as >98%, since the amount of viral RNA penetrating in 1 hr across an uncoated membrane was 11,016 copies, whereas <300 copies, the lower limit of detection, penetrated the endothelial-astrocyte barrier during this time interval. Following treatment with TNF-a, the model became increasingly permeable to the virus with time after infection and with basal permeability of each model (compare the fibronectin matrix models in Fig. 3A with the collagen 1-fibronectin matrix model in Fig. 3B ), and with TNF-a dosage (Figs. 3C and 4) . ANOVA indicated that there was a significant linear relationship (p = 0.042, F = 2.747) between log TNF-a concentration and log p24 antigen concentration, such that for every log unit change in TNF-a, there was a 0.2 log unit change in p24 antigen.
No threshold for TNF-a effect was found in the concentration range 1 to 100 ng/ml (Fig. 4) . The relative contribution of each component of the model to HIV barrier function was measured by HIV RNA assay. Brain endothelial cells provided >99% of the barrier function, whereas astrocytes contributed negligibly either alone or together with endothelial cells (Fig. 5) .
HIV-1 p24 antigen permeability was compared in models constructed on fibronectin or the collagen 1-fibronectin matrix. Virus inocu- bl .5 million copies of HIV RNA were placed in the lower chamber.
C250,000 monocytes were placed in the upper chamber. The numbers (mean ± S.E.M.) indicate the number of monocytes that transmigrated at indicated times across the terephthalate membrane (pore size 8 ,um) with or without endothelial/astrocyte bilayer into the lower chamber at indicated times.
lum (2100 pg of the antigen) was placed in the upper chamber. HIV p24 antigen efficiently penetrated the barrier in direct relation to the permeability such that 21 hr after the infection, 91 ± 8 pg/ml of p24 antigen penetrated the high-permeability fibronectin-based barrier and 50 ± 5 pg/ml penetrated the low-permeability collagen 1-fibronectin-based barrier.
HIV-1 Activation of Brain Endothelial
Cells for IL-6 Secretion but Not Infection Brain endothelial cells (40,000) were exposed to HIV-1 (20 pg, 1.5 x 106 RNA copies) and thoroughly washed. Virus adsorption was measured after 1 hr by the RNA assay, which revealed only 321 RNA copies associated with the cells. The cultures were monitored for 1 month but no infectious virus or viral antigen were released even after TNF-a challenge as described in Materials and Methods. The supernatant medium of virus-exposed endothelial cells, which was assayed at weekly intervals, revealed persistent IL-6 secretion with maximum titers of 54-68 U/ml, compared with unexposed cells producing at most 3-5 U/ml.
HIV-1 in the Brain Compartment Attracts Transmigration of Monocytes
The increase in monocyte infiltration of the brain with progression of AIDS dementia suggests that invading HIV-1 may be a stimulus for monocyte immigration, which is in agreement with the ability of HIV-1 to induce macrophage inflammatory proteins-1a and -13 (MIP-1a and -1(3) (39).
Monocyte migration was therefore assayed in the models (with or without endothelial-astrocytic bilayer) modified by inclusion of monocytes alone or with HIV-1 in the lower chamber as a chemotactic stimulus. Monocytes alone produced a slight stimulus (14-23% increase in monocyte migration in the presence of 10,000 monocytes in the lower chamber), which was increased substantially (44-58% increase by the addition of HIV-1 and monocytes to the lower chamber). This increase was noted at 24-48 hr post-infection, i.e., 1 to 2 days before onset of virus replication in monocytes (39) ( (47) .
In addition to the effects on endothelial cells, TNF-a has a wide range of pathogenetic mechanisms in patients with AIDS dementia that injure neurons and glia (35) and oligodendrocytes (48) , and that increase virus replication in macrophages and microglia (49) .
Cell Migration and Routes of HIV-1 Brain Invasion In macaques inoculated with SIV, infected macrophages can be found in the brain in a perivascular location early after infection (50, 51) . However, it is not known whether these infected macrophages represent cells migrating across the BBB, potentially introducing the virus into the CNS, or whether perivascular macrophages are simply the initial target of SIV infection in the brain. In the BBB model used as a representation of established AIDS dementia, LPS-activated monocytes show increased ability for transmigration (1 1). In a similar BBB model, CD4+ CD45RA ("memory") T cells show preferential transmigration compared with CD4+CD45RA+
("naive") T cells (17) .
Early in HIV-1 infection of humans, proviral DNA sequences are found almost exclusively in circulating CD4+ T cells, rather than in monocytes (52) . In contrast, plasma HIV-1 viremia titer is extremely high (15) . In patients with AIDS dementia, productive infection in the brain is confined almost exclusively to macrophages and microglia. On the basis of these observations, HIV-1 could potentially use several routes for brain invasion: early after the infection, it could use the paracellular route taken by cell-free virus and viral peptides, or be transported by activated CD4+ T cells; and in a late stage, it could be transported by infected monocytes (53, 54) . (39) . In the in vitro model, monocyte migration into the brain compartment 561 was stimulated by cell-free HIV-1 with kinetics preceding virus replication and MIP-1 production (39) , which suggests that HIV-1 peptides are chemotactic for monocytes. Collectively this evidence suggests that cell-free HIV-1 and virus peptides are the first to penetrate into the brain and induce brain inflammation.
In conclusion, brain microvascular endothelial cells are the principal barrier against HIV-1 infection of the central nervous system, which upon infection is overcome by cell-free HIV-1 potentially using several routes, including a paracellular route opened by TNF-a. The BBB model may help to identify specific cytokines and chemokines as well as their inhibitors that act on the BBB in vitro. This could lead to the identification of immune mechanisms that unravel the BBB in vivo and to the designing of new strategies for preventing HIV-1 infection of the brain during primary viremia.
